Alto Neuroscience (ANRO) EPS (Weighted Average and Diluted) (2023 - 2026)
Alto Neuroscience's (ANRO) quarterly EPS (Weighted Average and Diluted) came in at -$0.8 in Q1 2026, down 42.86% year-on-year from -$1.4 in Q1 2025, and down 77.78% quarter-over-quarter from -$0.45 in Q4 2025.
Alto Neuroscience (ANRO) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
Alto Neuroscience has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.8 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.8, down 42.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.42 (down 3.42% YoY), and the FY2025 annual result was -$2.19, up 12.4% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.8 for Q1 2026 at Alto Neuroscience, down from -$0.45 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.45 in Q4 2025 to a low of -$2.98 in Q4 2023.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.65 (2025), against an average of -$1.17.
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 81.21% in 2024 and sank 42.86% in 2026, its largest moves.
- Alto Neuroscience's EPS (Weighted Average and Diluted) stood at -$2.98 in 2023, then surged by 81.21% to -$0.56 in 2024, then gained by 19.64% to -$0.45 in 2025, then tumbled by 77.78% to -$0.8 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.8 (Q1 2026), -$0.45 (Q4 2025), and -$0.52 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Alto Neuroscience | 697.66 Mn | 433.90 Mn | - | -0.80 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.80 |
| Dec 31, 2025 | -0.45 |
| Sep 30, 2025 | -0.52 |
| Jun 30, 2025 | -0.65 |
| Mar 31, 2025 | -0.56 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | -0.62 |
| Jun 30, 2024 | -0.60 |
| Mar 31, 2024 | -0.76 |
| Dec 31, 2023 | -2.98 |
| Sep 30, 2023 | -2.44 |
| Jun 30, 2023 | -2.33 |
| Mar 31, 2023 | -1.97 |